Accessibility
Accessibility
Couple shopping in outdoor market, Bangkok, Bangkok, Thailand

Inheritest® carrier screen

Comprehensive insights for every reproductive journey

Inheritest Carrier Screen is part of a comprehensive offering for preconception to prenatal and from screening to diagnosis. Whether it’s clinical testing or complex genetics, Labcorp can fully support your practice to save time and optimize patient care.

“The primary goal of carrier screening is to facilitate informed reproductive decision making by identifying those [families] at risk of having an affected child with an (autosomal or X-linked) recessive disorder.”1

Why Inheritest®?

Inheritest provides carrier screening for more than 500 genes in a variety of panels designed to meet the evolving needs of your patients and your practice, throughout the entire reproductive journey.

Carrier screening with clinically relevant gene coverage

  • Multiple ethnic-neutral and multi-ethnic panels reflecting recent ACOG and ACMG recommendations 
  • Thoughtful disorder selection based on criteria such as severity and early childhood onset; inclusion of all known recessive and X-linked genes causing each disorder whenever possible, contributing to even higher detection rates2

Cutting-edge science and methodology

  • Full-gene sequencing with greater than 99% detection rates for most genes, and deletion/duplication analysis (copy number variant (CNV) calling)  
  • Enhanced SNP analysis to identify patients at risk to be silent (2+0) SMA genetic carriers3
  • One fast result for fragile X risk assessment, with both AGG and CGG repeats reported
     

Carrier screen with continuity of care and streamlined workflows

  • Multiple options for partner testing and reporting (with or without VUS) to identify more at-risk couples
  • Prenatal diagnosis for all disorders on Inheritest that may save time and reduce anxiety
  • Saliva and buccal swab specimen collection options 
Inheritest Provider Brochure(Opens in a new window) View Inheritest Panels
Mother and child

Why ethnic-neutral carrier screening?


The need for more equitable screening for every patient is becoming clear. In a recent Practice Resource, the American College of Medical Genetics and Genomics (ACMG) recommends that:

“Carrier screening paradigms should be ethnic and population neutral and more inclusive of diverse populations...”4

The American College of Obstetricians and Gynecologists (ACOG) states that carrier screening for spinal muscular atrophy (SMA), in addition to cystic fibrosis (CF), “should be offered to all women who are considering pregnancy or are currently pregnant.”5

Why is genetic carrier screening important?

dna icon

Everyone carries 3 to 5 mutations that could cause a genetic disorder6

male female

Approximately 1 to 2% of all couples are at risk for having a child affected with a severe recessive genetic disorder7

family tree

People may not know their family history or ethnic background8

Is genetic carrier screening necessary?

The absence of family history for genetic disease is not an indicator of decreased risk for having an affected child. For example, more than 80% of infants with CF are born to families with no prior family history.9

View Inheritest Panels

Still have questions?

Call 800-848-4436 (toll-free within the US)

Additional Resources

Costs Icon

Understanding Costs

Use our cost estimator get an immediate estimate for most tests we offer based on your specific insurance plan (so have your policy number handy).

Use Our Cost Estimator
Understand Your Results Icon

Understand Your Results

If you have already had a test, we can answer questions about your results.

View Results Info
Genetics Icon

Genetic Counseling

Genetic counselors translate and communicate genetic information into practical, understandable terms.

Learn More

References

  1. Henneman L, Borry P, Chokoshvili D, et al. Responsible implementation of expanded carrier screening. Eur J Hum Genet. 2016;24(6):e1-e12. doi:10.1038/ejhg.2015.271.
  2. Internal data
  3. Luo M, Liu L, Peter I, et al. An Ashkenazi Jewish SMN1 haplotype specific to duplication alleles improves pan-ethnic carrier screening for spinal muscular atrophy. American College of Medical Genetics and Genomics. online publication 20 June 2013. Doi:10.1038/gim.2013.84.
  4. Gregg AR, Aarabi M, Klugman S, et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23(10):1793-1806. doi:10.1038/s41436-021-01203-z.
  5. Carrier Screening for Genetic Conditions. Committee Opinion No. 691. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017;129:e41–55.
  6. Chong JX, Ouwenga R, Anderson RL, Waggoner DJ, Ober C. A population-based study of autosomal-recessive disease-causing mutations in a founder population. Am J Hum Genet. 2012;91(4):608-620. doi:10.1016/j.ajhg.2012.08.007. 
  7. Ropers HH. On the future of genetic risk assessment. J Community Genet. 2012;3(3):229-236. doi:10.1007/s12687-012-0092-2. 
  8. Lazarin GA, Haque IS, Nazareth S, et al. An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals. Genet Med. 2013;15(3):178-186. doi:10.1038/gim.2012.114.
  9. Wildhagen MF, ten Kate LP, Habbema JD. Screening for cystic fibrosis and its evaluation. Br Med Bull. 1998;54(4):857-875. doi:10.1093/oxfordjournals.bmb.a011734. Henneman L, Borry P, Chokoshvili D, et al. Responsible implementation of expanded carrier screening [published correction appears in Eur J Hum Genet. 2017 Nov;25(11):1291]. Eur J Hum Genet. 2016;24(6):e1-e12. doi:10.1038/ejhg.2015.271